Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
tambotatug pelitecan + serplulimab
- Development stage
- Unknown
- Lead developer
- Roche
- Modality
- Cytotoxic ADCs → Antibody-Drug Conjugates (ADCs) → Antibody Conjugates → Antibody-Based Therapeutics, Monoclonal Antibodies → Antibody-Based Therapeutics
- Administration
- Intravenous
01
Overview
tambotatug pelitecan + serplulimab is an investigational combination therapy consisting of tambotatug pelitecan (also known as YL201 or RG6919), a B7-H3 (CD276)-directed antibody-drug conjugate (ADC), and serplulimab (HLX10), a humanized anti-PD-1 monoclonal antibody. Tambotatug pelitecan utilizes a humanized anti-B7-H3 IgG1 monoclonal antibody conjugated to a topoisomerase I inhibitor payload (pelitecan, a camptothecin derivative) via a cleavable linker. Serplulimab is an approved immune checkpoint inhibitor targeting PD-1. The combination is designed to leverage the synergistic effects of ADC-mediated tumor cell cytotoxicity and immunotherapy-induced T-cell activation. It is currently being evaluated in a Phase 3 clinical trial (NCT07739758) as a first-line treatment for patients with treatment-naive extensive-stage small cell lung cancer (ES-SCLC).
- Other names
- RG6919 + serplulimabtambotatug pelitecan + HLX10YL201 + serplulimab
02
Targets
B7-H3PDCD1 (Programmed cell death protein 1 receptor)
Beyond the preview
Go deeper on tambotatug pelitecan + serplulimab.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on tambotatug pelitecan + serplulimab.